Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tharimmune ( (THAR) ) just unveiled an update.
On January 20, 2026, Tharimmune, Inc. announced it had priced a $55 million underwritten registered offering comprising 1.8 million shares of common stock at $2.92 per share and pre-funded warrants for up to 17 million additional shares at $2.9199 per warrant, with closing expected on or about January 21, 2026, subject to customary conditions. The capital raise, conducted under an effective shelf registration with Clear Street acting as sole bookrunner, is intended to provide growth capital to expand and further develop Tharimmune’s Canton-focused digital asset treasury strategy and to bolster working capital for general corporate purposes, underscoring the company’s ambition to scale its role in institutional blockchain infrastructure while supporting its broader operational needs.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) is a hybrid player at the intersection of digital assets and biotechnology, positioning itself as the first publicly traded company to leverage Canton Coin to support the Canton Network’s efforts to digitize traditional financial markets. Alongside its differentiated Canton-centric digital asset treasury strategy on a privacy-enabled blockchain hosting trillions in on-chain assets, the company also operates clinical-stage biotech research and development operations, targeting both institutional blockchain adoption and healthcare innovation.
Average Trading Volume: 1,416,849
Technical Sentiment Signal: Buy
Current Market Cap: $109.2M
See more data about THAR stock on TipRanks’ Stock Analysis page.